IMAGION BIOSYSTEMS - Australian Medical Device Company developing bio-safe medical imaging technologies.
SOI:- 508 Million + 96 Million options. MC:- $13.8 Million Share Price:- .027c Cash:- $5 Million ( Nov 2019)
• Innovative medical imaging using magnetic nanoparticles to identify and stage cancer early • Proprietary MagSenseTM technology is non-invasive and provides more specific & sensitive detection for cancer than current imaging technologies • Breakthrough - Technical feasibility and safety profile vetted,designated as a “breakthrough device” by FDA • Multiple commercial opportunities:- 1/ Proprietary MagSenseTM imaging technology 2/ Magnetic Resonance Imaging (MRI) contrast agent 3/ Therapy and/or drug delivery. • MagSenseTM technology complements existing imaging and is more cost effective than many existing imaging technologies • First-in-human studies on-track for 2020 – targeting metastatic breast cancer.
35% capacity utilization A$2.2 million annual revenue per instrument. Revenue through licensing/partnership fees Royalties or revenue share on tests. US$500K Capital Sale, 50% Gross Margin. US$1,500 / Test, 80% Gross Margin.
Indicative development timeline:
On track for first-in-human study in FY20 – study duration expected to be 3-6 months. First human data key validation point, paves way for discussion with commercial partners. GMP manufacturing of nanoparticles for use in human study key driver of schedule. FDA communication for approval to commence study in process, breakthrough status ensures expedited communication. Clinical site contract discussions initiated; MD Anderson and additional sites under consideration.
